

TECHNICAL PROTOCOL
FOR
FRT-PGK-gb2-neo-FRT
FRT flanked,
Pro- and Eukaryotic
Neomycin Selection Cassette
(A002)

CONTENTS

1 Eppendorf tubes + manual

1. FRT-PGK-gb2-neo-FRT: PCR template (50 ng/μl, 20μl)
2. This manual

Store tube at -20°C

Please read

The products listed in this manual are for research purposes only. They are not designed for diagnostic or therapeutic use in humans, animals or plants. The Red[®]/ET[®] recombination technology is the intellectual property of Gene Bridges GmbH.

Conditions of use

3.1 Purchaser will not manufacture, copy, reproduce, transmit, distribute, sell, lease, transfer, or improve upon the MATERIALS without prior written consent from GENE BRIDGES.

3.2 All MATERIALS relating Technologies shall be purchased from GENE BRIDGES or its authorized distributors. Use of any of the stated products from a source other than GENE BRIDGES will exempt GENE BRIDGES from any and all liabilities and warranties.

3.3 All MATERIALS purchased by research organizations, universities and other non-profit organizations may not be used for any commercial purpose. These MATERIALS are to be used for research purposes only. The MATERIALS may not be used to provide a commercial or non-commercial service, of any kind.

3.4 A purchase of MATERIALS by a private consumer is neither intended nor permitted.

Short Description:

“FRT-PGK-gb2-neo-FRT” template is designed to allow neomycin/kanamycin selection in prokaryotic and eukaryotic cells.

The FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance gene which combines a prokaryotic promoter (gb2) for expression of kanamycin resistance in *E.coli* with a eukaryotic promoter (PGK) for expression of neomycin resistance in mammalian cells.

The prokaryotic promoter gb2 is a slightly modified version of the Em7 promoter; it mediates higher transcription efficiency than the normally used Tn5 promoter. The promoter of the mouse Phosphoglucokinase gene (PGK) is used as eukaryotic promoter. A synthetic polyadenylation signal terminates the kanamycin/neomycin expression. The cassette is flanked by FRT sites for later excision by Flp-recombinase.

Using the provided PCR template one can easily create a FRT-PGK-gb2-neo-FRT cassette flanked by any restriction sites to clone the cassette into the vector of choice. The restriction sites can be introduced by adding the corresponding sequence in the PCR primer. The template can easily be used to generate targeting constructs mediated by a single Red/ET Recombination step.

The “FRT-PGK-gb2-neo-FRT template” is not linear but plasmid based (3446bp in size). Due to its R6K origin it can not replicate in most of the *E. coli* strains. The PCR product can therefore be used directly for downstream applications without any further purification.

At least 20 PCR reactions can be performed using 1µl per reaction as template.

Map: FRT-PGK-gb2-neo-FRT cassette



NotI

```

1  AATTAACCCTCACTAAAGG CCGGCCGC GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC ATTCTACCGG GTAGGGGAGG
82  CGCTTTTCCC AAGGCAGTCT GGAGCATGCG CTTTAGCAGC CCCGCTGGGC ACTTGGCGCT ACACAAGTGG CCTCTGGCCT
162  CGCACACATT CCACATCCAC CGGTAGGCGC CAACCGGCTC CGTTCTTTGG TGGCCCTTC GCGCCACCTT CCACTCTCC
242  CCTAGTCAGG AAGTTCCCCC CCGCCCCGCA GCTCGCGTCG TGCAGGACGT GACAAATGGA AGTAGCACGT CTCACTAGTC
322  TCGTGCAGAT GGACAGCACC GCTGAGCAAT GGAAGCGGGT AGGCCTTTGG GGCAGCGGCC AATAGCAGCT TTGCTCCTTC
402  GCTTTCTGGG CTCAGAGGCT GGAAGGGGT GGTCCGGGG GCGGGCTCAG GGCAGGGCTC AGGGCGGGG CGGGCGCCC
482  AAGGTCCTCC GGAGCCCCG CATTCTGCAC GCTTCAAAG CGCACGTCTG CCGCGCTGTT CTCCTCTTCC TCATCTCCG
562  GCCTTTCGAC C TGCAGC AGCACGTGTT GACAATTAAT CATCGGCATA GTATATCGGC ATAGTATAAT ACGACAAGT
639  GAGGAACTAA ACC ATG GGA TCG GCC ATT GAA CAA GAT GGA TTG CAC GCA GGT TCT CCG GCC GCT TGG
      1 Met Gly Ser Ala Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp
706  GTG GAG AGG CTA TTC GGC TAT GAC TGG GCA CAA CAG ACG ATC GGC TGC TCT GAT GCC GCC GTG TTC
      19 Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Gln Ser Asp Ala Ala Val Phe
772  CGG CTG TCA GCG CAG GGG CGC CCG GTT CTT TTT GTC AAG ACC GAC CTG TCC GGT GCC CTG AAT GAA
      41 Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu
838  CTG CAG GAC GAG GCA GCG CGG CTA TCG TGG CTG GCC ACG ACG GGC GTT CCT TGC GCA GCT GTG CTC
      63 Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Gln Ala Ala Val Leu
904  GAC GTT GTC ACT GAA GCG GGA AGG GAC TGG CTG CTA TTG GGC GAA GTG CCG GGG CAG GAT CTC CTG
      85 Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu
970  TCA TCT CAC CTT GCT CCT GCC GAG AAA GTA TCC ATC ATG GCT GAT GCA ATG CGG CGG CTG CAT ACG
      107 Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr
1036  CTT GAT CCG GCT ACC TGC CCA TTC GAC CAC CAA GCG AAA CAT CGC ATC GAG CGA GCA CGT ACT CGG
      129 Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg
1102  ATG GAA GCC GGT CTT GTC GAT CAG GAT GAT CTG GAC GAA GAG CAT CAG GGG CTC GCG CCA GCC GAA
      151 Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu
1168  CTG TTC GCC AGG CTC AAG GCG CGC ATG CCC GAC GGC GAG GAT CTC GTC GTG ACC CAT GGC GAT GCC
      173 Leu Phe Ala Arg Leu Lys Ala Arg Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala
1234  TGC TTG CCG AAT ATC ATG GTG GAA AAT GGC CGC TTT TCT GGA TTC ATC GAC TGT GGC CGG CTG GGT
      195 Gln Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Gln Gly Arg Leu Gly
1300  GTG GCG GAC CGC TAT CAG GAC ATA GCG TTG GCT ACC CGT GAT ATT GCT GAA GAG CTT GGC GGC GAA
      217 Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu
1366  TGG GCT GAC CGC TTC CTC GTG CTT TAC GGT ATC GCC GCT CCC GAT TCG CAG CGC ATC GCC TTC TAT
      239 Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr
1432  CGC CTT CTT GAC GAG TTC TTC TGA GCGGACTCTGGGGTTCGAATAAAGACCGACCAAGCGAC GTC TGA
      261 Arg Leu Leu Asp Glu Phe Phe
1501  GAGCTCCCTG GCGAATTCGG TACCAATAAA AGAGCTTTAT TTTCATGATC TGTGTGTTGG TTTTGTGTG CGGCGCG GAA
      XhoI
1581  GTTCCTATTCTCTAGAAAGTATAGGAACTTC C TCGAGCCCTATAGTGAGTCGTATTA

```

Please take into consideration that the sequence given above does not reflect the complete plasmid but refers to the functional cassette.